Article
Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapy.
Cancer biology & therapy - 2 Oct 2020
Price Timothy, Ang Agnes, Boedigheimer Michael, Kim Tae Won, Li Jin, Cascinu Stefano, Ruff Paul, Satya Suresh Attili, Thomas Anne, Tjulandin Sergei, Peeters Marc
Abstract excerpt
BACKGROUND: Antibodies against epidermal growth factor receptor (EGFR), panitumumab, a fully human monoclonal antibody, and cetuximab, a human/mouse chimeric monoclonal antibody, have shown clinical efficacy in metastatic colorectal cancer (mCRC). In the phase 3 noninferiority ASPECCT (ClinicalTrials.gov, NCT01001377) study, panitumumab was demonstrated to be noninferior to cetuximab and provided a similar...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.